P2-CRC-D0918Active studySynthetic mock data
ctDNA-guided adjuvant de-escalation
Recurrence-free survival, 24 mo
Phase
II
Enrollment
87/160
54%
Sites
9
Readout
2027-Q4
Waterfall — best % change in target-lesion sum (P2-CRC-D0918)
Per-subject best response from baseline. Sorted descending. Reference lines at PR (-30%) and PD (+20%) thresholds.
CR (2)PR (1)SD (2)PD (0)
5 subjects, sorted by best responseDrill into study →
Protocol summary
- Sponsor
- Vanq Translational Lab
- Status
- enrolling
- Start date
- 2025-02-04
- Arms
- 2
- Sites
- 9
- Primary endpoint
- Recurrence-free survival, 24 mo
Endpoints assigned to this study
Subjects in P2-CRC-D0918
5 subjects with serial RECIST measurements
Featured subject
Sara Khan · s-0918-007 · MRN 6025307
RECIST 1.1 — Target lesions
Serial measurements (mm) and per-visit response
Sum-of-diameters; % from baseline (PR ≤ -30%); % from nadir (PD ≥ +20% absolute ≥ 5 mm)
| Lesion | Modality | Baseline2025-09-04 | Wk 82025-10-30 | Wk 162025-12-25 | Wk 242026-02-19 | Wk 322026-04-16 |
|---|---|---|---|---|---|---|
Pelvic node | CT | 16 | 12 | 9 | 8 | 7 |
| Sum of diameters | mm | 16 | 12 | 9 | 8 | 7 |
| % from baseline | 0.0% | -25.0% | -43.7% | -50.0% | -56.2% | |
| % from nadir | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| RECIST response | NE | PR | PR | PR | PR |
Non-target lesions
Per-visit qualitative status (presence / absence / equivocal / new)
| Lesion | Baseline | Wk 8 | Wk 16 | Wk 24 | Wk 32 |
|---|---|---|---|---|---|
| Anastomotic thickening | present | present | equivocal | absent | absent |
Cohorts in P2-CRC-D0918
Cross-links